Clinical evidence of transformation to a more aggressive subtype of lymphoma
History of transformation of indolent disease to DLBCL (expansion-phase only)
Histologically confirmed, biopsy-proven diagnosis of DLBCL, BCLu, HGBCL, or TiNHL. Richter's transformation from Chronic Lymphocytic Leukemia (CLL) is not eligible.
Richter's transformation from CLL
Richters transformation confirmed by biopsy
History of Richter's transformation from CLL
CLL WITH RICHTER's TRANSFORMATION (ARM C) ONLY
Presence of more than % pro-lymphocytes in peripheral blood; patients with Richter's transformation are not excluded
Known histological transformation to an aggressive lymphoma
Richter's transformation confirmed by biopsy
Active Richters transformation
Known histological transformation to an aggressive lymphoma (ie, Richter transformation). Note: Biopsy documentation of the absence or presence of transformation is not required.
For patients with Richters transformation, one prior line of therapy for either CLL or Richters transformation (RT) is required
Richter transformation.
Richter transformation
Patients with previously treated CLL and biopsy-proven Richters transformation with diffuse large B-cell lymphoma (DLBCL) histology according to International Workshop on Chronic Lymphocytic Leukemia (IWCLL) criteria (Richter Transformation - RT) and CD positive by flow cytometry OR immunohistochemistry.
Richters transformation confirmed by biopsy
CLL patients with known or suspected transformed disease (i.e. Richters transformation)\r\n* Note: biopsy proven absence of transformation is not required
Large cell transformation
Confirmed diagnosis of B-cell Chronic Lymphocytic Leukemia or Richter's Transformation
Participants with CLL or DLBCL who have Richter's Transformation
Evidence ongoing transformation into aggressive NHL
CLL patients with active transformed disease (Richters transformation) are ineligible for enrollment on this study
Known histological transformation from CLL to an aggressive lymphoma (Richter's)
Richter's transformation (DLBCL arising in the setting of prior chronic lymphocytic leukemia) or Primary Mediastinal B cell Lymphoma (PMBCL)
If the subjects has Richter's Syndrome (RS), the diagnosis is confirmed by biopsy and is immunohistologically characterized as transformation to DLBCL.
Known histological transformation from iNHL or CLL to an aggressive form of non-Hodgkin lymphoma (ie, Richter transformation) except if the CLL patient is enrolling in the B-cell receptor (BCR) previously treated cohort
Transformation of CLL to aggressive Non-Hodgkin's Lymphoma (NHL) (Richter's transformation)
Evidence of disease transformation at the time of study entry
Transformation of CLL to aggressive Non-Hodgkin's Lymphoma (NHL) (Richter's transformation)
Presence of more than % pro-lymphocytes in peripheral blood; patients with Richters transformation are not excluded
History of transformation of indolent disease to DLBCL
Active Richters transformation
Cohort B-: ) Histologically-confirmed Richter syndrome defined as transformation of CLL or SLL into an aggressive lymphoma ) Previously treated with at least one line of standard, systemic chemotherapy or not eligible for standard therapy ) At least  measurable site of disease based on the Revised Response Criteria for Malignant Lymphoma
Transformation of CLL to aggressive non-Hodgkin's lymphoma (Richter's transformation)
Transformation of CLL to aggressive Non-Hodgkin's Lymphoma (NHL) (Richter's transformation)
Transformation of CLL to aggressive Non-Hodgkin's lymphoma (Richter's transformation or pro-lymphocytic leukemia)
Subject has developed Richter's transformation confirmed by biopsy
Transformation of CLL to aggressive non-Hodgkin lymphoma or central nervous system (CNS) involvement by CLL
Subjects with Richter's transformation
Known central nervous system leukemia/lymphoma or Richter's transformation
Presence of disease transformation from a previously diagnosed low-grade lymphoma
CLL patients with transformed disease (Richter's transformation) are ineligible for enrollment on this study
Follicular lymphoma with histology documented by the participating institution (grades ,  or a)\r\n* For subjects with presumptive evidence of transformation based on clinical assessment of factors such as, but not limited to, increasing lactate dehydrogenase (LDH), rapidly worsening disease, or frequent B-symptoms, a pre-treatment biopsy is required to rule out large cell transformation
Subjects with known SCLC transformation
CLL transformation
Known histological transformation from CLL to an aggressive lymphoma (ie, Richter transformation)
Known histological transformation from CLL to an aggressive lymphoma (ie, Richter transformation)
Richter's transformation, arising in the setting of prior CLL, documented by histologically confirmed lymphoma, including large B-cell and immunoblastic variants.
Known histological transformation from CLL to an aggressive lymphoma (ie, Richter transformation)
Patients with B-CLL (not in Richters transformation) with measurable disease
History of transformation of indolent disease to DLBCL
Active disease transformation (ie, Richter's Syndrome); subjects with Richter's Syndrome that has resolved >  years from signing the ICD are eligible.
Evidence of aggressive or highly aggressive lymphoma or Richters transformation based on WHO/REAL classification criteria()
Pathologic evidence of malignant transformation
History of transformation of indolent disease to DLBCL
Known transformation of CLL (e.g. Richter's).
Known transformation to an aggressive B-cell malignancy.
Transformation of CLL to aggressive Non-Hodgkin's Lymphoma (NHL) (Richter's transformation)
Patients with Richters transformation are not allowed in the study
Patients with the Hodgkin variant transformation of CLL will be excluded
Known histological transformation from iNHL to diffuse large B-cell lymphoma or Richters transformation for CLL
Richter's transformation or CLL transformation to aggressive lymphoma
